Welcome to our dedicated page for PROKIDNEY SEC filings (Ticker: PROK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ProKidney Corp. filings document a late clinical-stage biotechnology issuer focused on rilparencel, an autologous renal cell therapy candidate for chronic kidney disease in patients with diabetes. Recent Form 8-K reports furnish operating and financial results, Regulation FD investor presentations, clinical-study and development-plan updates, FDA-pathway disclosures, financial-position information, and material-event or material-agreement disclosures.
Proxy materials describe annual meeting proposals, board elections, auditor ratification, stockholder voting procedures, and governance matters for the public company.
PROKIDNEY CORP. (PROK) director Brian J. G. Pereira reported six sales of Class A Common Stock over August 18–20, 2026, totaling 757,164 shares. Sales included both direct holdings and shares held indirectly by the Brian J. G. Pereira 2012 Irrevocable Trust, at weighted average prices between $1.345 and $1.50 per share in open market or private transactions.
ProKidney Corp. (PROK) is the issuer for a notice of proposed sale of restricted or control securities under Rule 144. Director Brian Pereira, through the Brian Pereira 2012 Trust, has filed to sell 675,235 shares of ProKidney common stock that were acquired on January 17, 2022 for cash. Merrill Lynch Pierce Fenner & Smith is listed as the broker, and a prior sale of 27,826 common shares on August 18, 2026 for $38,154.23 is also reported.
ProKidney Corp. (PROK) received a Rule 144 notice indicating that director Brian Pereira plans to sell common stock. The notice lists a planned sale of 114,000 shares of common stock of ProKidney through Merrill Lynch Pierce Fenner and Smith on NASDAQ. It also discloses that a related holder, the Brian Pereira 2012 Irrevocable Trust, has sold 229,338 shares of ProKidney common stock over the past three months for $314,462.14.
Morgan Stanley and an affiliate reported their current ownership in ProKidney Corp. Class A common stock on a Schedule 13G/A amendment. Morgan Stanley reported aggregate beneficial ownership of 9,653,756 shares with 4.7% of the class, all through shared voting and dispositive power. Morgan Stanley Investment Management Inc. reported beneficial ownership of 9,642,992 shares, also representing 4.7% of the class, with no sole voting or dispositive power. Both entities stated that, as of the reporting date, each has ceased to be the beneficial owner of more than five percent of this class of securities.
ProKidney Corp. reported second quarter 2026 results and progress on its lead cell therapy program rilparencel for advanced chronic kidney disease with type 2 diabetes. Enrollment was completed for the Phase 3 PROACT 1 accelerated approval efficacy analysis, expected to include about 320 patients using annualized eGFR slope as a surrogate endpoint, with topline results anticipated in Q2 2027. Full enrollment of approximately 470 patients for the confirmatory time-to-event analysis is targeted for the second half of 2026, with topline results anticipated in the second half of 2029.
ProKidney ended Q2 2026 with $181.6 million in cash, cash equivalents and marketable securities, which the company expects will fund operations into mid-2027. For the quarter, research and development expenses were $36.1 million and general and administrative expenses were $12.4 million. Net loss before noncontrolling interest was $46.4 million, and net loss available to Class A common stockholders was $28.4 million, or $0.15 per basic and diluted share. Net cash used in operating activities for the first six months of 2026 was $82.1 million.
The company strengthened its leadership by appointing Kenneth Locke as Chief Technical Officer, bringing more than 25 years of R&D, CMC and supply chain experience as ProKidney advances toward potential regulatory and commercial milestones for rilparencel.
ProKidney Corp., a late-clinical-stage biotech developing the autologous cell therapy rilparencel for advanced diabetic CKD, reported continued operating losses and a strained liquidity position for the quarter and six months ended June 30, 2026.
For the first half of 2026, revenue from building lease income was $0.4 million, while operating expenses reached $93.7 million, driven mainly by research and development of $69.9 million and general and administrative costs of $23.7 million. Net loss before noncontrolling interest was $89.1 million, compared with $74.9 million a year earlier, and net loss attributable to Class A shareholders was $48.5 million, or $0.29 per share.
Cash and cash equivalents plus marketable securities totaled $181.6 million at June 30, 2026, down from $270.0 million at year-end 2025. Management states there is substantial doubt about the company’s ability to continue as a going concern, as existing liquidity is not expected to fund obligations for 12 months following the August 10, 2026 filing date without additional financing or strategic arrangements. The Phase 3 PROACT 1 study has completed enrollment for patients contributing to the accelerated-approval surrogate endpoint, with topline eGFR slope data expected in the second quarter of 2027.
ProKidney Corp. director Brian J.G. Pereira reported exchanging paired Class B common stock and ProKidney Holdings, LLC common units into Class A common stock on August 4, 2026. He converted 81,929 paired securities held directly and 675,235 held through the Brian J. G. Pereira 2012 Irrevocable Trust, receiving equal numbers of Class A shares at a stated price of $0.00 per share. The corresponding Class B and LLC common unit interests for these amounts were reduced to zero.
PROKIDNEY CORP. reported that Chief Technical Officer Kenneth Thomas Locke received an employee stock option grant covering 750,000 shares of Class A Common Stock. The options have an exercise price of $1.8900 per share and expire on July 1, 2036.
The award is compensation-related rather than an open-market purchase. According to the vesting terms, 25% of the option vests on the first anniversary of July 1, 2026, with the remaining 75% vesting in substantially equal monthly installments over the following 36 months, subject to continued employment. Following this grant, Locke holds 750,000 derivative securities directly.
PROKIDNEY CORP. Chief Legal Officer Todd C. Girolamo converted paired interests into common stock. On June 12, 2026, he converted 163,857 Class B Common Stock and an equal number of Common Units in ProKidney Holdings, LLC into 163,857 shares of Class A Common Stock at $0.00 per share.
Following the conversion, he directly holds 327,713 shares of Class A Common Stock. The paired Class B shares and Common Units were originally received in the business combination with ProKidney LP and were exchangeable on a one-for-one basis into Class A shares.
PROKIDNEY CORP. executive Kenneth Thomas Locke, the company’s Chief Technical Officer, has filed an initial Form 3 insider ownership report. This filing establishes his status as an officer subject to insider reporting rules. The data provided show no reported purchases, sales, or other equity transactions in this submission.